2026-04-16 · medications, wegovy, semaglutide, glp-1

Wegovy for Weight Loss

Who this is for / not for

Good fit if:

• You are an adult with obesity (BMI 30 or higher), or overweight (BMI 27 or higher) with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol.
• You want a once-weekly injectable option with strong appetite effects and you can follow a stepwise dose titration schedule.
• You are ready to pair medication with nutrition, activity, and ongoing clinician follow-up.

Not a fit if:

• You have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
• You have a history of pancreatitis, severe gastrointestinal disease, or significant gastroparesis without specialist clearance.
• You are pregnant, breastfeeding, or planning pregnancy in the near term.

What Wegovy is

Wegovy is the U.S. brand name for semaglutide when prescribed for chronic weight management. It is a once-weekly subcutaneous injection that was first approved by the FDA in 2021 for adults with obesity, or adults who are overweight and have at least one weight-related condition, as an addition to a reduced-calorie diet and increased physical activity.

Wegovy contains the same molecule as Ozempic (semaglutide), but it is dosed higher and is approved specifically for weight management rather than type 2 diabetes. For a broader view of the underlying drug, see the semaglutide for weight loss article and the GLP-1 weight loss overview.

How it works

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. In plain terms, it mimics a gut hormone your body normally releases after meals. Acting on GLP-1 receptors:

• Slows the rate at which the stomach empties, so meals feel filling for longer.
• Reduces appetite and food-related cravings signals in the brain.
• Improves satiety after eating, so portions are easier to keep smaller.

These effects combine to reduce daily calorie intake without the sharp hunger swings that usually follow aggressive dieting. Wegovy works best alongside structured nutrition and physical activity habits; it is not a substitute for lifestyle change.

Expected weight loss

Wegovy’s expected results come mainly from the STEP clinical trial program. In STEP 1, a 68-week randomized trial in adults with overweight or obesity who did not have diabetes, average total body weight loss was about 14.9% at the 2.4 mg weekly maintenance dose, compared with about 2.4% in the placebo group.

STEP 4 looked at what happens when people keep taking the drug versus stop. Participants who continued weekly semaglutide kept losing weight and maintained most of their loss, while those switched to placebo gradually regained a meaningful share of what they had lost. The pattern is consistent with how most chronic weight management drugs behave: the effect depends on ongoing treatment plus lifestyle support.

Individual results vary. Most people see early appetite changes in the first weeks, with steady weight loss accumulating over several months at the maintenance dose.

Dosing and administration

Wegovy is a subcutaneous injection given once a week, on the same day each week, in the stomach, thigh, or upper arm. Dosing starts low and increases in steps to reduce side effects.

Typical titration schedule (4 weeks at each step):

• 0.25 mg once weekly
• 0.5 mg once weekly
• 1.0 mg once weekly
• 1.7 mg once weekly
• 2.4 mg once weekly (maintenance)

If a dose is missed and the next scheduled dose is more than 2 days away, the manufacturer advises taking the missed dose as soon as possible. If the next dose is less than 2 days away, skip the missed dose and take the next dose on the regular day. Follow the product label for exact timing and storage instructions.

Side effects and safety

Most side effects are gastrointestinal, dose-related, and tend to improve as the body adjusts to each new dose.

Common side effects:

• Nausea, vomiting, diarrhea, constipation.
• Decreased appetite, abdominal pain, reflux, burping.
• Injection-site reactions, fatigue, headache.

Serious or less common risks:

• Boxed warning for thyroid C-cell tumors based on rodent data; avoid in people with a personal or family history of medullary thyroid carcinoma or MEN2.
• Pancreatitis: stop the drug and seek care for persistent severe abdominal pain.
• Gallbladder disease, including gallstones and cholecystitis.
• Acute kidney injury, usually linked to dehydration from vomiting or diarrhea.
• Hypoglycemia, particularly when Wegovy is combined with insulin or sulfonylureas.
• Mood changes and suicidal thoughts have been reported across the GLP-1 class; postmarketing surveillance is ongoing.

For a deeper look at class-wide safety, see weight loss drug safety. Since Wegovy and Ozempic share the same molecule, the side-effect profiles overlap closely with what is described in Ozempic side effects.

Cost and access

In the U.S., Wegovy’s list price is roughly $1,300 per month for a one-month supply of weekly pens, though actual out-of-pocket cost depends on insurance.

Typical access points:

• Commercial insurance: Coverage for weight-loss drugs varies widely by plan. Prior authorization is common and often requires documentation of BMI, prior weight-loss attempts, and related conditions.
• Medicare: Medicare Part D generally does not cover drugs used strictly for weight loss, so Wegovy is typically not covered for weight management alone. Some plans may cover it when prescribed for a separate approved indication such as reducing cardiovascular risk in adults with obesity and existing heart disease.
• Manufacturer support: Novo Nordisk has offered a Wegovy savings card for eligible commercial plans.
• Compounded semaglutide: Compounded semaglutide is not FDA-approved, has not been reviewed by the FDA for safety, efficacy, or quality, and has been the subject of FDA safety communications about dosing errors, ingredient concerns, and adverse events. The narrow shortage-era rules that allowed wider compounding have tightened, so the legal and safety landscape can change quickly.

Plan for recurring monthly costs for as long as you remain on therapy, plus clinician visits and any labs your prescriber orders.

Wegovy vs Ozempic and Zepbound (brief)

Wegovy, Ozempic, and Zepbound are often grouped together, but they are not interchangeable.

• Wegovy vs Ozempic: Same molecule (semaglutide), different approved uses and doses. Ozempic is approved for type 2 diabetes and is dosed up to 2.0 mg weekly. Wegovy is approved for chronic weight management and is dosed up to 2.4 mg weekly. Insurance rules differ. For more on Ozempic in a weight management context, see Ozempic for weight loss.
• Wegovy vs Zepbound: Different molecules. Wegovy targets GLP-1 only. Zepbound (tirzepatide) targets both GIP and GLP-1. Across available trial data, average total body weight loss tends to be higher with tirzepatide, while semaglutide has longer real-world safety experience and dedicated cardiovascular outcome data. Side-effect profiles are broadly similar; individual tolerability, insurance coverage, and clinician judgment drive most real-world choices.

For a closer comparison, see Zepbound for weight loss and semaglutide vs tirzepatide.

Frequently asked questions

Is Wegovy the same as Ozempic? The active ingredient is identical (semaglutide). Wegovy is the brand approved for chronic weight management and is dosed up to 2.4 mg weekly. Ozempic is the brand approved for type 2 diabetes and is dosed up to 2.0 mg weekly. Insurance coverage rules and approved uses differ.

Do you keep the weight off after stopping Wegovy? Usually not completely. In STEP 4, people who continued semaglutide kept losing or maintained their weight, while those who stopped regained a meaningful share of what they had lost. Plan for long-term use, or a structured maintenance plan, rather than a short course.

What if you miss a dose? If the next scheduled dose is more than 2 days away, take the missed dose as soon as possible. If it is less than 2 days away, skip the missed dose and resume your regular weekly schedule. Do not double up. Follow the product label for exact guidance.

Is Wegovy covered by insurance? It depends on the plan. Commercial plans increasingly cover Wegovy with prior authorization for people who meet BMI and clinical criteria. Medicare generally does not cover weight-loss-only drugs, although coverage may apply under some plans for FDA-approved non-weight-loss indications (such as reducing cardiovascular risk in eligible patients). Medicaid coverage varies by state.

Is compounded semaglutide safe? Compounded semaglutide is not FDA-approved. The FDA has warned about dosing errors, sterility concerns, and adverse events linked to compounded versions, and the shortage-era rules that previously allowed wider compounding have tightened. If cost is the main barrier, ask your prescriber about manufacturer savings programs or branded options before considering compounding.

Can you drink alcohol on Wegovy? There is no strict prohibition, but alcohol can worsen nausea, reflux, and low blood sugar risk, especially during dose escalation. Many people find their tolerance for alcohol is lower than before starting treatment.

Practical next steps

This week

• Confirm whether your BMI and conditions meet FDA criteria for Wegovy, and whether your insurance lists it on the formulary.
• Ask your prescriber about a titration plan, a consistent injection day, and how to reach them for side-effect questions.
• Start a simple log of weight, appetite, and any GI symptoms so you have trend data for follow-ups.

What to track

• Weekly weight trend and appetite changes.
• GI symptoms (nausea, vomiting, diarrhea, constipation) and hydration.
• Protein intake, resistance training sessions, and sleep.

How to know it is working

• Appetite feels lower and portion sizes are easier to manage.
• Weight loss accumulates steadily over months rather than pounds in a single week.
• Side effects peak briefly after each dose step, then ease.

How this article was researched

This article draws on the STEP clinical trial program for semaglutide in chronic weight management (notably STEP 1 and STEP 4), the FDA approval announcement for Wegovy, and FDA prescribing information and safety communications. Cost and coverage details reflect publicly posted manufacturer and payer information at the time of writing.